Urologist, Surgeon-scientist, Immune-oncology, Kidney cancer, Associate Research Scientist, Faculty @YaleMed @YaleCancer https://xitter.gq/t.co/fiYnlM7kWl
New Haven, CT
Joined September 2022
- Tweets267
- Following344
- Followers231
- Likes951
Pinned Tweet
I thrilled to share our review and Beyond the Abstract on “The Changing Landscape of Immunotherapy for Advanced Renal Cancer” from sciencedirect.com/science/ar… and urotoday.com/recent-abstract…
I really appreciate @BraunMDPhD's mentoring
@UroToday @YaleCancer @YaleMed
@UrologicClinics
The changing landscape of immunotherapy for advanced #RenalCancer. #BeyondTheAbstract with @KashimaMDPhD and @BraunMDPhD @YaleCancer. #ReadNow on UroToday > bit.ly/3CPrXmY @YaleMed @UrologicClinics
Soki Kashima retweeted
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy.
🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.
#BladderCancer #GUOnc @OncoAlert @BladderCancerUS
Soki Kashima retweeted
Why is ADC development in RCC challenging?Great overview by @YujiMiura5 highlighting 3 barriers:
Delivery: heterogeneous vasculature limits ADC penetration. Targeting: antigen heterogeneity & vascular trapping. Payload: efficacy vs toxicity
Time to rethink targets & payloads!
@myESMO @oncoalert #ESMO26
Soki Kashima retweeted
Everyone should listen to a @BraunMDPhD talk at least quarterly (doctor's orders!)
Fantastic talk focused on personalized cancer vaccines in RCC. Looking forward to the results of INTerpath-004!
#ESMO26 @OncoAlert
Great talk by @BradMcG04 at the JSCO–ASCO Joint Session @official_jsco on perioperative therapy for RCC
Adjuvant therapy is evolving rapidly, but identifying who truly benefits remains a key challenge. Exciting potential for biomarkers like KIM-1!
#JSCO2026 #RCC #KidneyCancer
Soki Kashima retweeted
New @jclinicalinvest study led by @BraunMDPhD @YaleCancer and super star Dr Madsen : HIF-2α inhibition with belzutifan preserves T-cell effector function in ccRCC—supporting the rationale for combining HIF-2α and PD-1 blockade without compromising T-cell activity.
Reassuring translational evidence!
jci.org/articles/view/204613
Soki Kashima retweeted
Congratulations to @romeerizwan and team on this exciting work in @CD_AACR —a terrific collaboration (that includes our @DanaFarber_GU group) on spatially confined IL-12 + CAR-NK biology.
And a very pleasant surprise on the same page: seeing @BraunMDPhD, now at @YaleCancer featured as the 2026 Cancer Discovery Journal Awardee. Full-circle moment!
@DanaFarber @DanaFarberNews @harvardmed
Now online: Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks doi.org/10.1158/2159-8290.CD…
ARiSE採択課題一覧
jst.go.jp/pr/info/info1875/p…
やはりデジタルツインは世間の期待が大きい。
基盤モデル作りも大事。
実用化やインフラ化の道筋は課題になりそう。
Soki Kashima retweeted
The Academy of Kidney Cancer Investigators is a DOD-funded mentoring Academy of the next generation of RCC leaders. Our monthly didactic lectures on RCC topics from leaders in the field is available here:
youtube.com/@AcademyofKidney…
Soki Kashima retweeted
FDA grants Priority Review for the VOLGA trail, in which 3 neoadjuvant cycles of EV and a year of Perioperative durvalumab was given for patients with muscle invasive bladder cancer. Press release states an EFS and OS advantage. Data will be presented #ESMO26 @OncoAlert @myESMO @Annals_Oncology astrazeneca-us.com/content/a…
Soki Kashima retweeted
Personalized mRNA-based neoantigen vaccines + pembo are being tested in a number of randomised adjuvant cancer trials (included bladder and renal). The 1st positive trial (RIII in melanoma) was announced today. PCVs are logistically complex with limited monotherapy activity in advanced disease, but early IO combinations in MRD may overcome tumor microenvironment resistance. Patient selection or even vaccine generation could occur with ctDNA. @OncoAlert merck.com/news/merck-and-mod…
Soki Kashima retweeted
I’m excited to ride in my 2nd #CloserToFree on Sept. 19! As a Yale PhD student, YCC has supported my training and kidney cancer research in @BraunMDPhD’s lab. I’m proud to help raise funds for patients & families at Smilow and cancer research. 🚴♀️
rideclosertofree.org/partici…
Soki Kashima retweeted
What better way to start Day 2 than by crossing the starting line together?
This morning, #KCRS26 attendees laced up for #RockTheRun, a fun tradition that reminds us that every step, whether on the course or in the lab, helps move #KidneyCancer research forward.
Thank you to everyone who ran, walked, volunteered, donated, and cheered us on. Together, we're making progress one step at a time.
There’s still time to donate: bit.ly/RocktheRun26
#AcceleratingCures
Soki Kashima retweeted
Toni Choueiri @DrChoueiri receiving the lifetime achievement award #KCRS26 . Leading a plethora of practice changing trials from METEOR to LITESPARK. >900 publications. Amazing achievement and well deserved.
Soki Kashima retweeted
🎉 Excited to share that our paper on single-cell RNA sequencing of Hunner-type interstitial cystitis has been published in iScience! 🚀
We identified a previously unrecognized cell population. Thank you so much to everyone who made this work possible!🙌
doi.org/10.1016/j.isci.2026.…
Soki Kashima retweeted
筆頭論文がNature誌@Natureに掲載されました！
1563例の急性骨髄性白血病(AML)でクロマチン解析を行い、遺伝子変異だけでなく、エピゲノムの変化も白血病の発症メカニズムや個性を理解する上で重要であることを示した世界初の大規模研究です。(1/10)
nature.com/articles/s41586-0…
Soki Kashima retweeted
本気の研究が揃い踏みです😮
横浜市大泌尿器科 軸屋良介先生によるHLRCCのmulti-Omics解析の研究を紹介します
#JSRC26
@jsrc_1991